A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with PEG-IFN α-2a and Tenofovir Disoproxil Fumarate

Trial Profile

A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with PEG-IFN α-2a and Tenofovir Disoproxil Fumarate

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs ARB 1467 (Primary) ; Interferon; Tenofovir
  • Indications Hepatitis B
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Arbutus Biopharma
  • Most Recent Events

    • 09 Feb 2018 Status changed from planning to recruiting.
    • 02 Nov 2017 According to an Arbutus Biopharma media release, the company expects to initiate this study in the fourth quarter of 2017; also interim results are expected in the second half of 2018, followed by final results in 2019.
    • 03 Aug 2017 According to an Arbutus Biopharma media release, this trial is expected to initiate in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top